Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome
NCT05726916Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2023
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of eculizumab in atypical hemolytic uremic syndrome (aHUS) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: 6-month response to therapy. Started Nov 2023; status: recruiting.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT05726916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05726916.